Gaush Meditech (HKSE:02407) ROCE %: 5.26% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02407 Gaush Meditech Ltd HKSE:02407
67 GF Score
Price HK$4.93
GF Value HK$13.39
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Gaush Meditech ROCE %?

Gaush Meditech HKSE:02407 +0.61% 67 ROCE % is 5.26% as of Dec. 2025. GuruFocus rates HKSE:02407 with a GF Score™ of 67/100 and a GF Value™ of HK$13.39 (Possible Value Trap). The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Gaush Meditech's annualized ROCE % for the quarter that ended in Dec. 2025 was 5.26%.

Gaush Meditech  (HKSE:02407) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Gaush Meditech ROCE % Related Terms

Gaush Meditech ROCE % Historical Data

* Premium members only.

The historical data trend for Gaush Meditech's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gaush Meditech ROCE % Chart

Gaush Meditech Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial -3.74 -10.56 14.13 9.47 6.46

Gaush Meditech Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.51 7.80 10.92 7.52 5.26
HKSE:02407
67GF Score
Gaush Meditech Ltd HKSE:02407
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gaush Meditech ROCE % Calculation

Gaush Meditech's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=148.335/( ( (2739.979 - 546.45) + (2898.855 - 498.418) )/ 2 )
=148.335/( (2193.529+2400.437)/ 2 )
=148.335/2296.983
=6.46 %

Gaush Meditech's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=124.542/( ( (2812.691 - 476.085) + (2898.855 - 498.418) )/ 2 )
=124.542/( ( 2336.606 + 2400.437 )/ 2 )
=124.542/2368.5215
=5.26 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 5.26% mean?
Gaush Meditech (HKSE:02407) has a ROCE % of 5.26% as of Dec. 2025.
Is Gaush Meditech's ROCE % too high?
Gaush Meditech's current ROCE % is 5.26%. The Medical Devices & Instruments industry median ROCE % is 2.22. Gaush Meditech's value of 5.26% is 136.9% above this industry median. Overall, Gaush Meditech has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Gaush Meditech's ROCE % compare to ABT and SYK?
Gaush Meditech's ROCE % of 5.26% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.22. Gaush Meditech's value of 5.26% is 136.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.22, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gaush Meditech's current ROCE % of 5.26% is 136.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gaush Meditech's current ROCE % is 5.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gaush Meditech stock overvalued right now?
Based on GuruFocus' analysis, Gaush Meditech (HKSE:02407) is currently considered Possible Value Trap. The stock's GF Value™ is HK$13.39, compared to a current price of HK$4.93 — trading 63.2% below its estimated fair value. The current ROCE % is 5.26% and 136.9% above the Medical Devices & Instruments industry median of 2.22. Gaush Meditech's overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Gaush Meditech (HKSE:02407), the current ROCE % is 5.26% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gaush Meditech (HKSE:02407) Overvalued in 2026?

Based on GuruFocus' analysis, Gaush Meditech stock appears to be undervalued. The current stock price of HK$4.93 is trading 63.2% below its estimated GF Value™ of HK$13.39. GuruFocus considers Gaush Meditech to be Possible Value Trap.

Key valuation signals for HKSE:02407:

  • ROCE %: 5.26%
  • GF Value™: HK$13.39 vs. price of HK$4.93 (63.2% below fair value)
  • GF Score™: 67/100 with 3 warning signs
  • Industry Position: 136.9% above the Medical Devices & Instruments median

No single metric tells the full story. See the HKSE:02407 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gaush Meditech Business Description

Other Exchanges F7Y:Germany
Address No.11 Dongzhimen South Avenue, Room 1901, Building A, Zhonghui Plaza, Dongcheng District, Beijing, CHN
Gaush Meditech Ltd is a provider of a broad spectrum of manufacture and sale ophthalmic medical devices and provision of technical services. The segments of the company include Proprietary products segment that derives maximum revenue, develops and produces surgical equipment and related supporting software, intra-optical lens, ophthalmic disease diagnosis and treatment equipment and related supporting consumables independently; Distribution products segment sells multi-function diagnostic equipment, ocular fundus diagnosis, surgical and treatment equipment and related supporting consumables produced by ophthalmic medical equipment manufacturers; Technical services segment provides warranty services, maintenance services and other related consumables; and Others segment.
67GF Score

Get the complete analysis for HKSE:02407

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$4.93
Price
HK$13.39
GF Value